[ET Net News Agency, 20 January 2022] Luye Pharma Group Ltd. (02186) said the United
States Food and Drug Administration has granted its approval for initiating clinical
trials for the group's new central nervous system (CNS) drug LY03009.
LY03009 is indicated for the treatment of Parkinson's disease and restless legs
syndrome. It has been developed on the group's long-acting and extended release technology
platform. (RC)